Nouvelle déclaration d'incident
No de la demande: 2013-6318
Numéro de référence du titulaire d'homologation: 2013CK089
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer Inc
Adresse: 77 Belfield Rd
Ville: Toronto
État: ON
Pays: Canada
Code postal /Zip: M9W 1G6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-142
Nom du produit: K9 Advantix II Medium dog
Liquide
Oui
Unités: mL
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Dog / Chien
Scottish Terrier
1
Femme
12
20
lbs
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
Unknown / Inconnu
Système
Unknown / Inconnu
Inconnu
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
on an unknown date post administration the owner noted scabs, erythema and skin lesions at the application site. The dog was also lethargic and developed vomiting and diarrhea. Approximately 1 month later the dog recovered from all clinical signs but had a scar at the application site. On an unspecified date in 2012 the dog passed away from unknown causes, as a necropsy was not performed. No further information expected. Case closed. Note: Specifics about the event were vague, as the caller had a hard time recalling specifics
Mort
While application site erythema may occur in particular sensitive dogs after product application, scab and lesions at the application site are not expected. Dog likely, though not reported, scratched at site and caused skin lesions by selftrauma with subsequent development of scabs. The scar at application site, also unexpected, is a late consequence of skin disorders. However, duration of first course is unexpected long and the medical history conditions (atopic allergy and pruritus) of the dog may have contributed to the delayed recovery. For the reported lethargy and digestive disorders time to onset is unknown. Signs are very unspecific and dog is reported to be in fair condition. Other causes are more probable, but signs may have multiple potential causes in geriatric dogs (12 years). Death is not expected in dogs after product application, as inconsistent with pharmacotoxicological product profile. Very low level of information (unknown time to onset for death, no necropsy was performed) and details about the event were hard to remember for the owner. This is explainable by the fact, that last application of the product had been in 2011, patient died in 2012 and the report of the owner was received recently. Considering all aspects and point in time of owners call, a product connection is deemed to be unlikely.